BioRestorative Therapies, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that BioRestorative Therapies, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $81.0K | Apr 2, 2018 |
| FY2017 | Dec 31, 2016 | $36.4K | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $628.9K | Mar 22, 2017 |
| FY2015 | Dec 31, 2014 | $416.0K | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | $1.7K | Mar 31, 2015 |
| FY2013 | Dec 31, 2012 | $15.6K | Apr 11, 2014 |
| FY2012 | Dec 31, 2011 | $0 | Apr 2, 2013 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $359.7K | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $401.0K | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $145.8K | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $119.8K | Jun 11, 2024 |
| FY2022 | Dec 31, 2021 | $46.0K | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $77.0K | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $130.0K | Apr 30, 2021 |
| FY2019 | Dec 31, 2018 | $111.0K | Mar 18, 2021 |
| FY2018 | Dec 31, 2017 | $81.0K | Mar 29, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($14.24M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($8.98M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($10.42M) | Mar 28, 2025 |
| FY2023 | Sep 30, 2023 | $4.77M | Jun 11, 2024 |
| FY2023 | Jun 30, 2023 | ($5.71M) | Jun 11, 2024 |
| FY2023 | Mar 31, 2023 | ($7.17M) | Jun 11, 2024 |
| FY2023 | Dec 31, 2022 | ($13.22M) | Jun 11, 2024 |
| FY2023 | Sep 30, 2022 | ($5.45M) | Jun 11, 2024 |
| FY2023 | Jun 30, 2022 | $3.10M | Jun 11, 2024 |
| FY2023 | Mar 31, 2022 | ($8.21M) | Jun 11, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($15.65M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($11.56M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($15.22M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($18.97M) | Jun 11, 2024 |
| FY2022 | Dec 31, 2021 | ($26.31M) | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | ($2.75M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($8.43M) | Apr 30, 2021 |
| FY2019 | Dec 31, 2018 | ($7.65M) | Mar 18, 2021 |
| FY2018 | Dec 31, 2017 | ($8.37M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($7.79M) | Apr 2, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.08M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $12.28M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $12.61M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $16.43M | Jun 11, 2024 |
| FY2022 | Dec 31, 2021 | $22.45M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $4.35M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $1.47M | Apr 30, 2021 |
| FY2019 | Dec 31, 2018 | $1.19M | Mar 18, 2021 |
| FY2018 | Dec 31, 2017 | $1.76M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $1.58M | Apr 2, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $3.75M | Mar 28, 2025 |
| FY2024 | Dec 31, 2023 | $2.61M | Mar 28, 2025 |
| FY2023 | Sep 30, 2023 | $3.04M | Jun 11, 2024 |
| FY2023 | Jun 30, 2023 | $10.66M | Jun 11, 2024 |
| FY2023 | Mar 31, 2023 | $7.62M | Jun 11, 2024 |
| FY2023 | Dec 31, 2022 | $6.14M | Jun 11, 2024 |
| FY2023 | Sep 30, 2022 | $8.14M | Jun 11, 2024 |
| FY2023 | Jun 30, 2022 | $7.29M | Jun 11, 2024 |
| FY2023 | Mar 31, 2022 | $14.97M | Jun 11, 2024 |
| FY2022 | Dec 31, 2021 | $856.5K | Mar 27, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $356.7K | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $8.53M | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | $10.00M | Mar 26, 2026 |
| FY2023 | Sep 30, 2023 | $10.76M | Jun 11, 2024 |
| FY2023 | Jun 30, 2023 | $2.64M | Jun 11, 2024 |
| FY2023 | Mar 31, 2023 | $6.46M | Jun 11, 2024 |
| FY2024 | Dec 31, 2022 | $10.29M | Mar 28, 2025 |
| FY2023 | Sep 30, 2022 | $9.78M | Jun 11, 2024 |
| FY2023 | Jun 30, 2022 | $12.16M | Jun 11, 2024 |
| FY2023 | Mar 31, 2022 | $5.95M | Jun 11, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 28, 2025 |
| FY2023 | Sep 30, 2023 | 1 | Jun 11, 2024 |
| FY2023 | Jun 30, 2023 | (1) | Jun 11, 2024 |
| FY2023 | Mar 31, 2023 | (1) | Jun 11, 2024 |
| FY2023 | Dec 31, 2022 | (3) | Jun 11, 2024 |
| FY2023 | Sep 30, 2022 | (1) | Jun 11, 2024 |
| FY2023 | Jun 30, 2022 | 0 | Jun 11, 2024 |
| FY2023 | Mar 31, 2022 | (2) | Jun 11, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 28, 2025 |
| FY2023 | Sep 30, 2023 | 0 | Jun 11, 2024 |
| FY2023 | Jun 30, 2023 | (1) | Jun 11, 2024 |
| FY2023 | Mar 31, 2023 | (1) | Jun 11, 2024 |
| FY2023 | Dec 31, 2022 | (3) | Jun 11, 2024 |
| FY2023 | Sep 30, 2022 | (1) | Jun 11, 2024 |
| FY2023 | Jun 30, 2022 | 0 | Jun 11, 2024 |
| FY2023 | Mar 31, 2022 | (2) | Jun 11, 2024 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.51M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $547.9K | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $884.4K | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $1.71M | Jun 11, 2024 |
| FY2022 | Dec 31, 2021 | $21.03M | Mar 27, 2023 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $250.0K | Mar 30, 2022 |